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Abstract
Excess adiposity has been shown to play a crucial role in the development of the metabolic
syndrome. The elevated fasting and postprandial triglyceride-rich lipoprotein levels is the central
lipid abnormality observed in the metabolic syndrome. Recent studies have indicated that
diacylglycerol (DAG) is effective for fasting and postprandial hyperlipidemia and preventing excess
adiposity by increasing postprandial energy expenditure. We will here discuss the mechanisms of
DAG-mediated improvements in hyperlipidemia and in postprandial energy expenditure, and
effects of DAG oil on lipid/glucose metabolism and on body fat. Further, the therapeutic application
of DAG for the metabolic syndrome will be considered.
Introduction
Visceral fat accumulation has been shown to play a crucial
role in the development of the metabolic syndrome,
which is highly atherogenic. Dyslipidemia associated with
the metabolic syndrome are elevated fasting and post-
prandial triglyceride (TG)-rich lipoproteins and decreased
high-density lipoprotein (HDL) [1]. Insulin resistance
resulting from obesity decreases lipoprotein lipase (LPL)
activity, and then, a reduced LPL activity leads to the
decreased clearance of fasting and postprandial TG-rich
lipoproteins and to the decreased production of HDL [1].
The elevated level of fasting and postprandial TG-rich
lipoproteins is the typical lipid abnormality observed in
the metabolic syndrome [1].
Diacylglycerol (DAG) oil is present in edible vegetable
oils. Recent studies have indicated that DAG is effective
for fasting and postprandial hyperlipidemia and for pre-
venting excess adiposity [2]. We will here discuss the ther-
apeutic application of DAG for the metabolic syndrome.
Biochemical properties of DAG
DAG is a natural component of various edible oils (Table
1) [3,4]. DAG can be synthesized enzymatically with the
reverse reaction of 1,3-specific lipase, and consists mainly
of the 1,3-species due to the migration of the acyl group
in an equilibrium reaction. The ratio of the 1,3-DAG to
1,2-DAG in DAG oil is approximately 7:3 (Fig. 1) [2].
The mechanism of DAG-mediated 
improvement in postprandial hyperlipidemia
Dietary TAG oil is hydrolyzed by lipase to free fatty acids
(FFA) and 2-monoacylglycerol in the small intestinal
lumen, and these are absorbed by intestinal cells (Fig. 2).
In intestinal cells, TG is re-synthesized from 2-monoacylg-
lycerol and two FFA via the 2-monoacylglycerol pathway
[5]. Monoacylglycerol acyltransferase (MGAT) and dia-
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cylglycerol acyltransferase (DGAT) work in the 2-monoa-
cylglycerol pathway [6,7]. TG is incorporated into
chylomicrons (CM) by microsomal triglyceride transfer
protein (MTP), which are released into the intestinal
lymph and poured into the bloodstream [8].
In the case of DAG oil, the metabolic pathway in the intes-
tinal cells is different from that of TAG oil (Fig. 3). Dietary
DAG oil is mainly in the form of 1,3-DAG. 1,3-DAG
would be hydrolyzed to initially to 1-monoacylglycerol
and then, to glycerol and FFA, which are absorbed into the
intestinal cells [9]. TG cannot be synthesized from 1-
monoacylglycerol via the 2-monoacylglycerol pathway in
the intestinal cells, because 1-monoacylglycerol cannot be
the substrate for both DGAT and MGAT [6,7]. TG could be
synthesized via the glycerol-3-phosphate pathway, which
is less active than the 2-monoacylglycerol pathway [10].
1,2-DAG would be hydrolyzed to 2-monoacylglycerol,
and TG is synthesized via the 2-monoacylglycerol path-
way [2].
Recently, Yasunaga K, et al found that DAG oil reduced
plasma TG levels, resulting from more efficient clearance
of DAG by both LPL-mediated lipolysis and apolipopro-
tein E-mediated hepatic endocytosis [11]. In also Sprague-
Dawley rats, a lower plasma TG levels was accompanied
by an increase in adipocyte LPL activity [12].
At present, slower re-acylation to TAG in small intestinal
cells, an increase in LPL activity and apolipoprotein E-
mediated hepatic endocytosis are supposed to be the
underlying mechanisms improving the postprandial
hyperlipidemia by substitution of DAG for TAG ingestion.
Effects of DAG oil on lipid and glucose 
metabolism
An outline of reported effects of DAG on lipid/glucose
metabolism is shown in Table 2. In animals, DAG inges-
tion was demonstrated to reduce plasma TG and FFA lev-
els compared with TAG ingestion. Fujii A, et al found that
DAG-rich oil reduced atherosclerosis in diabetic apoE-
deficient mice, and ingestion of DAG-rich oil was associ-
ated with reduction in plasma cholesterol levels within
larger TG-rich lipoproteins [13]. Further, DAG ingestion
was reported to prevent the high-sucrose-diet-induced
development of impaired glucose tolerance compared
with TAG oil ingestion, in male Wistar rats [14].
In our previous studies with healthy volunteers, serum TG
and remnant-like lipoprotein particles-cholesterol (RLP-
C) concentrations after DAG ingestion were significantly
lower than those after TAG ingestion [15]. Tomonobu K,
et al. also reported that postprandial TG, RLP-C, and CM-
TG concentrations were significantly lower after DAG
ingestion than after TAG ingestion [16]. In our study with
diabetic patients, DAG loading significantly suppressed
increases in postprandial serum TG, RLP-C and RLP-TG
levels as compared with TAG loading [17].
Recent study found that DAG reduced postprandial
increase in TG, RLP-C, and RLP-TG, especially in subjects
with insulin resistance [18]. In the subjects who con-
sumed daily 10 g of DAG for 12 weeks, serum TG levels
were decreased by 39.4%, and serum hemoglobin A1c lev-
els were also decreased by 9.7%, compared with subjects
who consumed TAG, suggesting that DAG ingestion also
ameliorates glucose metabolism [19]. Further, a long-
term DAG oil consumption has been reported to increase
HDL-C, and decrease fasting TG, total cholesterol, LDL-C,
compared with TAG consumption [20-22].
The apolipoprotein C-II is a cofactor of LPL, which hydro-
lyzes TG of CM and very-low-density lipoprotein (VLDL)
[23]. We have a therapeutic experience with DAG oil to a
patient with apolipoprotein C-II deficiency, a rare auto-
somal recessively-inherited disease [24]. In a patient with
Structure of triacylglycerol and diacylglycerol Figure 1
Structure of triacylglycerol and diacylglycerol. R1, R2, and R3 
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Table 1: Contents (weight %) of triacylglycerol and diacylglycerol 
in various edible oils [3,4]
Triacylglycerol Diacylglycerol
Soybean oil 97.9 1.0
Cottonseed oil 87.0 9.5
Palm oil 93.1 5.8
Corn oil 95.8 2.8
Safflower oil 96.0 2.1
Olive oil 93.3 5.5
Rapeseed oil 96.8 0.8
Lard 97.9 1.3Nutrition Journal 2007, 6:43 http://www.nutritionj.com/content/6/1/43
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apolipoprotein C-II deficiency, DAG ingestion suppressed
increase in serum TG, VLDL-C, and RLP-C levels com-
pared with TAG ingestion, suggesting that DAG can
decrease TG-rich lipoprotein, also independent of LPL.
In summary, DAG ameliorates fasting and postprandial
TG-rich lipoproteins, and glucose metabolism, which
may be favorable for metabolic disorders observed in the
metabolic syndrome.
The mechanism to promote negative caloric 
balance by DAG ingestion
Compared with the TAG-containing meal, the DAG-con-
taining meal tended to induce higher postprandial energy
expenditure and significantly lower postprandial respira-
tory quotient, suggesting that the DAG-containing meal
has high postprandial lipid oxidation activity and a poten-
tial effect on high diet-induced thermogenesis [25,26].
Upregulated mRNA expressions associated with FA trans-
port (FA translocase and FA binding protein), β-oxidation
(acyl-CoA oxidase and medium-chain acyl-CoA dehydro-
genase), and thermogenesis (uncoupling protein-2) in the
small intestine by DAG may explain in part mechanisms
for increased postprandial energy expenditure [27,28].
Effect of a long-term consumption of dietary 
DAG for adiposity
An outline of a long-term effect of DAG ingestion on body
composition is shown in Table 3. In rats, DAG-rich oil
ingestion was effective in suppressing FA synthase activity
and enhancing β-oxidation activity, reducing the abdom-
inal fat [29]. In brown adipose tissue-deficient mice, a
model of high-fat diet-induced insulin resistance and
obesity, a long term substitution of DAG for TAG reduced
Digestion and absorption of triacylglycerol Figure 2
Digestion and absorption of triacylglycerol. DGAT, diacylglycerol acyltransferase; FFA, free fatty acids; 2-MAG, 2-monoacylg-
lycerol; MGAT, monoacylglycerol acyltransferase; MTP, microsomal triglyceride transfer protein; TAG, triacylglycerol.
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Western-type diets induced insulin resistance and body fat
accumulation by suppressing hepatic gluconeogenesis
and stimulating fat oxidation in skeletal muscle [30].
A long-term consumption of DAG decreased body fat,
especially visceral fat, and decreased body weight in both
overweight and normal Japanese people, and obese sub-
jects in the United States, compared with TAG consump-
tion [31-33]. Open-labeled long-term consumption study
indicated that DAG decreased body weight compared
with TAG consumption [20]. In several long-term studies,
decrease in waist circumferences and skin fold thickness
by DAG consumption were observed [21,22,33].
Thus, several long-term clinical trials have indicated that
DAG consumption results in losses of body weight and
body fat, in healthy non-obese and obese men and
women. Further, DAG oil ingestion decreased both the
abdominal fat area and leptin in obese children, suggest-
ing that DAG oil prevents excess adiposity in children as
well as in adults [34]. Dairy ingestion of 8–20 g DAG has
been used in human studies on the effect of DAG on body
composition [35]. However, it remains unknown how
dose DAG is high effective for preventing excess adiposity,
which should be investigated in the future.
In summary, DAG may be beneficial in preventing excess
adiposity, which may be favorable for the metabolic syn-
drome.
A safety of a chronic consumption of DAG
In c-Ha-ras proto-oncogene transgenic rats, DAG oil
administration was associated with a significant increase
in the incidence of squamous cell carcinomas of the
tongue with the Cochran-Armitage trend test and also
number of tumors in coefficients for linear contrast trend
Digestion and absorption of diacylglycerol Figure 3
Digestion and absorption of diacylglycerol. DGAT, diacylglycerol acyltransferase; FFA, free fatty acids; 1(3)-MAG, 1-monoacylg-
lycerol or 3-monoacylglycerol; MGAT, monoacylglycerol acyltransferase; MTP, microsomal triglyceride transfer protein; TAG, 
triacylglycerol.
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tests [36]. However, 24 months-DAG-treated rats had no
higher risk of carcinogenic effects than rats fed on similar
feeding regimens with TAG [37]. The potential chronic
toxic effects of DAG when administered orally for 12
months were evaluated using Beagle dogs [38]. DAG at
dietary concentrations up to 9.5% for one year had no
effect on normal dog growth and development, in com-
parison to TAG [38]. In mice, DAG at dietary concentra-
tions up to 6.0% for 24 months produced no signs of
systemic toxicity and had no effect on the incidence of
neoplastic findings [39]. Most of studies investigating a
chronic dietary toxicity of DAG reported that DAG did not
produce systemic toxicity and had no effect on the inci-
dence of neoplastic findings. However, we should observe
the safety of a chronic consumption of DAG carefully.
Conclusion
DAG oil consumption has been reported to ameliorate
the constituents of the metabolic syndrome such as excess
adiposity, impaired glucose metabolism, and dyslipi-
demia, suggesting the usefulness of DAG oil for the man-
agement and prevention of the metabolic syndrome.
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